Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer Edith A. PerezTejal PatelAlvaro Moreno-Aspitia Review 13 March 2010 Pages: 261 - 271
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review Sekwon JangYoung Kwang ChaeNavneet S. Majhail Review 30 March 2010 Pages: 273 - 279
Health disparities in breast cancer: biology meets socioeconomic status Barbara K. DunnTanya Agurs-CollinsKaren A. Johnson Review 01 May 2010 Pages: 281 - 292
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence Lyndsay V. RhodesShannon E. MuirMatthew E. Burow Preclinical study 12 July 2009 Pages: 293 - 300
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines Cornelia LiedtkeJing WangLajos Pusztai Preclinical study 15 July 2009 Pages: 301 - 309
Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells Ying QuJinhua WangXiaojiang Cui Preclinical study 16 July 2009 Pages: 311 - 321
Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells Qun LiuAdam ShuhendlerXiao Yu Wu Preclinical study 18 July 2009 Pages: 323 - 333
Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine Meihua SuiDonghai JiangWeimin Fan Preclinical study 22 July 2009 Pages: 335 - 345
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers Lindsay A. BrownKarynn JohnsonDavid G. Huntsman Preclinical study 28 July 2009 Pages: 347 - 354
A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels Christine M. StellrechtMary AyresVarsha Gandhi Preclinical study 30 July 2009 Pages: 355 - 364
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer Marie KlintmanSidse Ørnbjerg WürtzNils Brünner Preclinical study 04 August 2009 Pages: 365 - 371
ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer Christoph HircheDawid MurawaMichael Hünerbein Clinical trial 07 February 2010 Pages: 373 - 378
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study Tomohiko AiharaYuichi TakatsukaYasuo Ohashi Clinical trial 14 April 2010 Pages: 379 - 387
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy Lori J. PierceKelly-Anne PhillipsSusan M. Domchek Clinical trial 22 April 2010 Pages: 389 - 398
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer Maurizia Mello-GrandVijay SinghGiovanna Chiorino Clinical trial 29 April 2010 Pages: 399 - 411
Three versus six months of exercise training in breast cancer survivors Lisa K. SprodCity C. HsiehCarole M. Schneider Clinical trial 05 May 2010 Pages: 413 - 419
Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema Rebecca M. SpeckCynthia R. GrossKathryn H. Schmitz Epidemiology 22 September 2009 Pages: 421 - 430
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia Marta SantistebanCarol ReynoldsLynn C. Hartmann Epidemiology 23 September 2009 Pages: 431 - 437
XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis Konstantinos P. EconomopoulosTheodoros N. Sergentanis Epidemiology 30 September 2009 Pages: 439 - 443
E-cadherin polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study Alicia Beeghly-FadielWei LuWei Zheng Epidemiology 16 October 2009 Pages: 445 - 452
Alcohol consumption and breast tumor mitochondrial DNA mutations Mary E. PlatekPeter G. ShieldsJo L. Freudenheim Epidemiology 22 October 2009 Pages: 453 - 460
Coffee and tea intake and risk of breast cancer Nirmala Bhoo PathyPetra PeetersCuno S. P. M. Uiterwaal Epidemiology 22 October 2009 Pages: 461 - 467
Meta-analysis of vitamin D, calcium and the prevention of breast cancer Peizhan ChenPingting HuHui Wang Epidemiology 23 October 2009 Pages: 469 - 477
The association of metabolic syndrome with triple-negative breast cancer B. MaitiM. N. KundrandaH. A. Daw Epidemiology 23 October 2009 Pages: 479 - 483
Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1 Ke-Da YuLei FanZhi-Ming Shao Epidemiology 24 October 2009 Pages: 485 - 496
No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk Irena E. AndonovaChristina JustenhovenHiltrud Brauch Epidemiology 27 October 2009 Pages: 497 - 502
Low SAFB levels are associated with worse outcome in breast cancer patients Stephanie Hammerich-HilleValerie J. BardoutSteffi Oesterreich Report 10 January 2009 Pages: 503 - 509
Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland Anna M. CzarneckaTomasz KrawczykJohn A. Petros Report 06 March 2009 Pages: 511 - 518
Health states of women after conservative surgery and radiation for breast cancer Gary M. FreedmanTianyu LiAndre Konski Brief Report 20 September 2009 Pages: 519 - 526
Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins Nasimeh AsgarianXiuying HuManijeh Pasdar Brief Report 29 September 2009 Pages: 527 - 538
